Idelalisib for the Treatment of Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia is the most common leukemia in the United States. It is a slowly progressive disease, with an 82% five-year survival rate. The treatment strategies are highly individualized with patients in the early and stable stages typically not requiring treatment. However, those wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Maliha, Saif, Areeba, Sandler, Steven, Mirrakhimov, Aibek E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003830/
https://www.ncbi.nlm.nih.gov/pubmed/25093123
http://dx.doi.org/10.1155/2014/931858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4003830/
https://www.ncbi.nlm.nih.gov/pubmed/25093123
http://dx.doi.org/10.1155/2014/931858

Ejemplares similares